Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also d
TMO
GOOGL, AMAT, AAPL, ANET, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, META, NVDA, SYK, BSX, ORCL, CBOE, PWR, MCK, NOW, ADBE, LYFT, SCHW, MCHP, ISRG, AMZN, ODFL, CRM
TFC, OMC, VZ, GILD, TSM
GILD
CVX, PFE
Karen Andersen
Sector Strategist